BEAM News and Press, Beam Therapeutics Inc. From 10/24/23

2023-10-24 08:05:14 ET More on Beam, CRISPR, etc. Beam: Opportunity Based On SCD Data Readout In 2024 Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy Editas Medicine: A Mispriced Contender In The Gene Editing Arena Beam extend...

2023-10-22 06:39:03 ET Summary Beam Therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle cell disease treatment; Data expected in 2024. The company has chosen to cut out several programs to conserve cash and prioritize long-term value f...

2023-10-21 08:45:00 ET Before taking the plunge into a pre-revenue gene-editing stock like Beam Therapeutics (NASDAQ: BEAM) , which is probably years away from making any money, it's important to pause for a beat to evaluate the arguments for and against an investment. The best time...

2023-10-20 12:45:56 ET More on Beam Therapeutics Beam Therapeutics: Rich In Cash, Poor In Punctuality (Rating Downgrade) Beam Therapeutics: Awaiting Clinical Progress And Path Towards Profitability Beam Therapeutics to cut 20% of workforce; sees cash runway into 2026...

2023-10-19 09:56:55 ET More on Beam Therapeutics Beam Therapeutics: Rich In Cash, Poor In Punctuality (Rating Downgrade) Beam Therapeutics: Awaiting Clinical Progress And Path Towards Profitability Seeking Alpha’s Quant Rating on Beam Therapeutics Hist...

Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to explore partnership opportunities for continued development of select programs ...

2023-10-19 03:53:32 ET Summary ARK Invest's 13F portfolio value decreased by 14% to $13.07B this quarter. The top three holdings in the portfolio are Tesla, UiPath, and Coinbase Global. ARK Invest increased its stakes in Block, Twilio, Roblox, Ginkgo Bioworks Holdings, and Rob...

2023-10-18 09:30:00 ET Biotech stocks, especially those that don't have a medicine on the market yet, tend to be among the riskiest investments available. Even under the best of conditions, clinical trials can fail to pan out in the way that management had hoped, and regulators can sometime...

2023-10-03 09:49:31 ET Summary Beam Therapeutics' Q2 2023 shows moderate revenue growth but rising operational costs, mainly in R&D, affecting net loss and diluting shares. Despite robust liquidity and a 33-month cash runway, operational inefficiencies in the BEACON sickle cel...

2023-10-03 06:27:00 ET This September, Cathie Wood bought shares of Beam Therapeutics (NASDAQ: BEAM) more than a dozen times for two of Ark Invest's exchange-traded funds ( ETF s). At the beginning of October, the biotech stock was the 13th-largest holding in the Ark Geno...